About MVASI

MVASI is a prescription medication containing the active ingredient bevacizumab, a recombinant humanized monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).

Key Benefits & Uses

Treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy.
Treatment of non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel.
Treatment of recurrent glioblastoma.
Treatment of metastatic renal cell carcinoma in combination with interferon alfa.
Treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel.

Active Ingredient & Action

Bevacizumab works by binding to VEGF-A, preventing its interaction with its receptors on the surface of endothelial cells, and thereby inhibiting angiogenesis. This action helps to slow the growth of cancer cells and reduce the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Important Notes

MVASI is intended for use under the guidance of a healthcare professional. Patients should be closely monitored for signs of hypertension, proteinuria, and bleeding. The medication may cause severe side effects, including gastrointestinal perforation, fistula formation, and wound healing complications. Patients should be advised to report any unusual symptoms or side effects to their healthcare provider promptly.